Supplemental Financial Data

6 Months Ended

Jun. 30, 2026

Supplemental Financial Data [Abstract]

3. Supplemental Financial Data

Inventories

Our inventories consisted of the following (in thousands):



		June 30, 2026		December 31, 2025
Raw materials	$	789	$	1,039
Work in process		49,465		24,051
Finished goods		579		1,096
Total	$	50,833	$	26,186
Reported as:
Inventories	$	50,833	$	10,048
Deposits and other assets		-		16,138
Total	$	50,833	$	26,186

We classify inventories as non-current assets when we expect the inventories to remain on hand beyond one year. We include non-current inventories in deposits and other assets in our condensed consolidated balance sheets. As a result of the FDA approval of TRYNGOLZA for the treatment of severe hypertriglyceridemia, or sHTG, in June 2026, we expect to utilize inventories on hand as of June 30, 2026 within one year. The amounts reported as deposits and other assets as of December 31, 2025 consisted of work in process inventory.

Accrued Liabilities

Our accrued liabilities consisted of the following (in thousands):


		June 30, 2026		December 31, 2025
Clinical expenses	$	54,949	$	53,659
In-licensing expenses		9,345		8,588
Commercial expenses, including gross-to-net product accruals		29,341		15,556
Other miscellaneous expenses		22,143		28,286
Total accrued liabilities	$	115,778	$	106,089